Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076407 · ClinicalTrials.gov registry record · Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
A Phase 3 study of Major Depressive Disorder, sponsored by Xenon Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT07076407 is a Phase 3 study of Major Depressive Disorder that is actively recruiting participants, run by Xenon Pharmaceuticals. The registered enrollment target is 450 participants, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT07076407, a Phase 3 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Xenon Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Azetukalner
Study Locations (20)
California
- Clinical Innovations Inc - Bellflower
- Center for Neurohealth - La Jolla
- Artemis Institute for Clinical Research - San Diego
- California Neuroscience Research - Sherman Oaks
- Pacific Clinical Research Management Group - Upland
Florida
- Gulfcoast Clinical Research Center - Fort Myers
- Sarkis Clinical Trials - Gainesville
- Equipath Health and Research Tampa Bay, Llc - Riverview
Massachusetts
- Adams Clinical Boston - Boston
- Activmed Practices & Research, Llc - Methuen - Methuen
- Adams Clinical Watertown - Watertown
Alabama
- Harmonex Neuroscience Research - Dothan
- University of Alabama at Birmingham, Huntsville Regional Medical Campus - Huntsville
Arkansas
- Pillar Clinical Research - Bentonville
- SanRo Clinical Research Group - Bryant
Connecticut
- Institute of Living - Hartford
Georgia
- Delricht Research - Atlanta
Illinois
- Advanced Quality Medical Research - Orland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-07-08 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07076407
The ClinicalTrials.gov registry entry for NCT07076407 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (20% higher). The listed sponsor is Xenon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07076407 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07076407 about?
NCT07076407 is a clinical study titled "A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)". X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
What is the current status of trial NCT07076407?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2025-07-08. Estimated completion is 2027-07.
What conditions does trial NCT07076407 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT07076407?
The interventions under investigation include: Placebo (DRUG), Azetukalner (DRUG).
Who is sponsoring clinical trial NCT07076407?
This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076407 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.